Physician profile
Taras Lisowsky
NPI 1710961990
$4,208.42
in general payments reported to CMS, 2019-2025
25 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $162 · 2021: $290 · 2022: $336 · 2023: $1,126 · 2024: $619 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $491.37 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $269.78 | 2019-2025 | |
| Exact Sciences Corporation | $233.64 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $230.83 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.49 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $191.20 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $140.89 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $127.76 | 2023-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $126.00 | 2023 | Dupixent |
| The Binding Site INC. | $106.74 | 2023 | Freelite |
| Novartis Pharmaceuticals Corporation | $97.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.78 | 2019 | |
| Phathom Pharmaceuticals, INC. | $80.65 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $74.38 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70.93 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $59.67 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $49.89 | 2023 | Yupelri |
| Dexcom, INC. | $42.69 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $24.40 | 2019 | |
| Daiichi Sankyo INC. | $22.34 | 2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $17.81 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.09 | 2023 | |
| Ibsa Pharma INC. | $13.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taras Lisowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.